🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our latest review on patients in the intermediate stage suggests that, thanks to recent positive phase studies on TACE combined with systemic therapy, the prospects for our patients will change dramatically Federica Lo Prinzi tandfonline.com/doi/full/10.10…

🔥off the press - our 🇪🇺RWD study: Atezolizumab/bevacizumab and lenvatinib for HCC Hepatology Communications doi.org/10.1097/HC9.00… 👉Similar OS for Lenva vs AB 👉Risk of hepatic decompensation for pts w/ impaired liver function under AB 🧐More data for clinical decision making ESMO - Eur. Oncology

Kicking off #ESMOImmuno24 with an inspiring talk by Prof. Tom Schumacher! Ready for three days full of cutting-edge insights on cancer immunotherapy

Wonderful presentation by Denis Migliorini at #ESMOImmuno24 on the landscape of cell therapies for GBM: T cells (promising poly-specifity through transient espression to tackle heterogeneity) and beyond (DCs and Macrophages rock!)

📢 HER2 and Biliary Tract Cancer: The Future of Targeted Therapies Our latest article delves into the current landscape and the emerging therapeutic strategies shaping the future of precision medicine. 📖 Read the full article here: link.springer.com/article/10.100…

Check our new work out in Cancer Research

🚨 What if a single DNA typo could inflame the body and outcompete healthy blood cells? 🧬 This happens in #VEXAS syndrome. In our paper out today in Nature Medicine we show how. 📖 Here: rb.gy/300drs 👇 A story of inflammation, clonal warfare and #CRISPR editing 🧵

Proud to share our meta-analysis just published! Anti-HER2 in BTC: -Best results with dual blockade & ADCs -Gallbladder & extrahepatic most responsive -mPFS 4.9 m…mOS 10.8 m A step forward for precision oncology in BTC. karger.com/ocl/article-ab…

🚨The *second* randomized clinical study to demonstrate significant survival benefit of T cell therapy Vs. standard of care for a relapsed/refractory solid cancer. Here, GEJ/gastric cancer using claudin 18.2 CAR-T. #Tecllpower thelancet.com/action/showPdf…

🚨 New in ESMO GI Oncology: In aHCC, early Bevacizumab dose mods = worse outcomes. 💡 <45 mg/kg in 3 months ➡️ ☠️ Higher mortality (HR 3.3) 📉 12-mo survival: 53% vs 77% ✅ Full-dose Beva is crucial with AtezBev. Federico Rossari authors.elsevier.com/sd/article/S29…